IFN-λ3 as a host immune response in acute hepatitis E virus infection.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
01 2020
Historique:
received: 21 12 2018
revised: 31 07 2019
accepted: 19 08 2019
pubmed: 30 8 2019
medline: 21 5 2021
entrez: 30 8 2019
Statut: ppublish

Résumé

Hepatitis E virus (HEV) is mainly transmitted orally, either waterborne or zoonotic foodborne. Intestinal viruses such as rotavirus are known to induce type III interferon (IFN) in the gastrointestinal (GI) tract where type III IFN dominantly functions in comparison with type I IFN. Therefore, the aim of this study is to investigate the significance of type III IFN (IFN-λ3) in acute hepatitis E. IFN-λ3 and HEV RNA levels in the sera of patients with acute HEV infection and in the supernatant of HEV-inoculated cells were measured, using an in-house high-sensitivity method and reverse transcription-polymerase chain reaction, respectively. High serum IFN-λ3 levels were found in the early phase of acute HEV infection, which normalized after resolution. Interestingly, serum IFN-λ3 levels correlated well with serum HEV RNA titers in the same sera, both of which showed the peak before the robust increase of transaminases. In vitro experiments demonstrated that HEV replicated well in the cells with little IFN-λ3 induction (Caco-2, A549) and recombinant IFN-λ3 inhibited HEV replication in a dose-dependent manner. In contrast, in HT-29 cells, a colon cancer cell line, HEV poorly replicated and induced IFN-λ3 in a titer-dependent manner. These clinical and experimental observations suggest that HEV induced IFN-λ3 as a host innate immune response, which may play a protective role against HEV.

Sections du résumé

BACKGROUND AND AIM
Hepatitis E virus (HEV) is mainly transmitted orally, either waterborne or zoonotic foodborne. Intestinal viruses such as rotavirus are known to induce type III interferon (IFN) in the gastrointestinal (GI) tract where type III IFN dominantly functions in comparison with type I IFN. Therefore, the aim of this study is to investigate the significance of type III IFN (IFN-λ3) in acute hepatitis E.
METHODS
IFN-λ3 and HEV RNA levels in the sera of patients with acute HEV infection and in the supernatant of HEV-inoculated cells were measured, using an in-house high-sensitivity method and reverse transcription-polymerase chain reaction, respectively.
RESULTS
High serum IFN-λ3 levels were found in the early phase of acute HEV infection, which normalized after resolution. Interestingly, serum IFN-λ3 levels correlated well with serum HEV RNA titers in the same sera, both of which showed the peak before the robust increase of transaminases. In vitro experiments demonstrated that HEV replicated well in the cells with little IFN-λ3 induction (Caco-2, A549) and recombinant IFN-λ3 inhibited HEV replication in a dose-dependent manner. In contrast, in HT-29 cells, a colon cancer cell line, HEV poorly replicated and induced IFN-λ3 in a titer-dependent manner.
CONCLUSIONS
These clinical and experimental observations suggest that HEV induced IFN-λ3 as a host innate immune response, which may play a protective role against HEV.

Identifiants

pubmed: 31465972
pii: S1043-4666(19)30245-5
doi: 10.1016/j.cyto.2019.154816
pii:
doi:

Substances chimiques

Interferon-alpha 0
Recombinant Proteins 0
Interferon-beta 77238-31-4
Interferons 9008-11-1
Transaminases EC 2.6.1.-
Interferon Lambda 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

154816

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Kazumoto Murata (K)

Department of Gastroenterology, Graduate School of Medical Sciences, International University of Health and Welfare, Nasushiobara, Japan; Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa, Japan. Electronic address: kmurata@iuhw.ac.jp.

Jong-Hon Kang (JH)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Shigeo Nagashima (S)

Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, Japan.

Takeshi Matsui (T)

Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

Yoshiyasu Karino (Y)

Department of Hepatology, Sapporo Kosei General Hospital, Sapporo, Japan.

Yoshiya Yamamoto (Y)

Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan.

Tomofumi Atarashi (T)

Department of Gastroenterology, Obihiro Kosei Hospital, Obihiro, Japan.

Masatsugu Oohara (M)

Department of Gastroenterology and Oncology, Kitami Red Cross Hospital, Kitami, Japan.

Minoru Uebayashi (M)

Department of Gastroenterology and Oncology, Kitami Red Cross Hospital, Kitami, Japan.

Hidekatsu Sakata (H)

Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan.

Keiji Matsubayashi (K)

Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.

Kazuaki Takahashi (K)

Department of Medical Sciences, Tokyo Shinagawa Hospital, Tokyo, Japan.

Masahiro Arai (M)

Department of Medical Sciences, Tokyo Shinagawa Hospital, Tokyo, Japan.

Shunji Mishiro (S)

Department of Medical Sciences, Tokyo Shinagawa Hospital, Tokyo, Japan.

Masaya Sugiyama (M)

Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa, Japan.

Masashi Mizokami (M)

Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa, Japan.

Hiroaki Okamoto (H)

Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH